2023-504280-16-00已完成1 期
A study to investigate JNJ-80202135 (nipocalimab) delivered subcutaneously via prefilled syringe autoinjector and via normal syringe
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CTIS Point of Contact
Scientific
Janssen - Cilag International
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A study to investigate JNJ-80202135 (nipocalimab) delivered subcutaneously via prefilled syringe autoinjector and via normal syringeHealthy VolunteersCTIS2023-504280-16-00Janssen - Cilag International60
招募中
1 期
A Phase 1b Study of JNJ-79635322 with Daratumumab With or Without Lenalidomide or JNJ-79635322 with Pomalidomide for Multiple MyelomaMultiple Myeloma2024-515316-44-00Janssen Cilag International32
招募中
1 期
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLLNon-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)2023-504187-42-00Janssen - Cilag International52
招募中
1 期
A Phase 1 Study of JNJ-87801493 in Combination with CD3 T-Cell EngagersNon-Hodgkin Lymphoid Malignancies2023-505165-93-00Janssen - Cilag International70
招募中
1 期
A Phase 1 Study of JNJ-87562761 in Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma2024-513439-25-00Janssen Cilag International15